- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
Policy Recommendations Connecticut
2019-2020 Improvements and Recommendations for Connecticut
Connecticut's program began with only 11 qualifying conditions but has expanded its list to a total of 27 conditions; six of which were added in 2019-2020. This list now includes chronic pain, an essential inclusion to combat opioid abuse.9 State officials expect the addition to double patient enrollment in the program in the coming years.10 Meanwhile Connecticut patients maintain the ability to demand new qualifying conditions via a petition to the state's regulatory authority. While the need for expansion continues there are now 17 dispensaries serving patients across the Constitution State.11
While much of the state's legislative efforts over the past two years have focused on adult-use legislation, ASA advises Connecticut state lawmakers and regulators to return focus to improving the state's medical program. Patient access remains challenging, and ASA recommends that state and local leaders collaborate to reduce local licensing barriers that are preventing expansion of medical cannabis retail and the functionality of medical access overall in the state. Medical cannabis is as important to the treatment of cannabis patients as traditional pharmaceutical products are to treating the conditions for which they are effective and appropriate. As such cannabis patients require the same ease of access to medical cannabis retail outlets that pharmaceutical patients do to pharmacies, and state and local elected leaders should work to facilitate access parity for both facility types.
One policy improvement worth considering to bolster patient access is the licensing of delivery from regulated storefronts and depots, which is also common among pharmacies. While the state declared cannabis businesses essential during the COVID pandemic, authorized telehealth visits for patient registration renewals, and allowed for curbside pickup during the pandemic, ASA encourages Connecticut to consider organizing a pilot program for delivery during this time that could be expanded in 2021 if successful. The state should also consider allowing home cultivation for patients as a means to expand access and reduce out-of-pocket costs for patients. Two other areas that ASA recommends focusing improvements on are consumer safety standards and staff training.